Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.5%

19 terminated/withdrawn out of 131 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

10%

13 trials in Phase 3/4

Results Transparency

37%

21 of 57 completed trials have results

Key Signals

15 recruiting21 with results13 terminated6 withdrawn

Enrollment Performance

Analytics

N/A

38(35.8%)

Phase 1

33(31.1%)

Phase 2

21(19.8%)

Phase 4

7(6.6%)

Phase 3

6(5.7%)

Early Phase 1

1(0.9%)

106Total

N/A(38)

Phase 1(33)

Phase 2(21)

Phase 4(7)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (131)

Showing 20 of 131 trials

NCT06788145Not ApplicableNot Yet Recruiting

Enhancing Social Connections Among Rural Community Members With Disordered Eating

Role: collaborator

NCT03289364Not ApplicableCompleted

Penguin Cold Caps in the Prevention of Hair Loss in Breast Cancer Patients

Role: lead

NCT01416831Phase 2Active Not Recruiting

Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.

Role: lead

NCT04373031Phase 2Active Not Recruiting

Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer

Role: lead

NCT05349890Phase 1Active Not Recruiting

Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Role: lead

NCT02734290Phase 1Active Not Recruiting

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

Role: lead

NCT05508984Active Not Recruiting

Clinical Outcomes and Patient Satisfaction With Use of the Amma System

Role: lead

NCT02812524Phase 1Active Not Recruiting

Ipilimumab for Head and Neck Cancer Patients

Role: lead

NCT04334707Recruiting

Kidney Precision Medicine Project

Role: collaborator

NCT04470024Phase 1Recruiting

Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC

Role: lead

NCT05913388Phase 2Recruiting

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

Role: lead

NCT02688712Phase 2Active Not Recruiting

ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

Role: lead

NCT04520711Phase 1Active Not Recruiting

Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Role: lead

NCT04895761Phase 1Active Not Recruiting

Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

Role: lead

NCT05249114Phase 1Active Not Recruiting

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Role: lead

NCT03650894Phase 2Active Not Recruiting

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Role: lead

NCT04061980Phase 2Active Not Recruiting

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

Role: lead

NCT04938609Phase 2Active Not Recruiting

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)

Role: lead

NCT07408856Phase 1Not Yet Recruiting

CAN1012 in Pre-Malignant DCIS and LCIS

Role: lead

NCT02422381Phase 1Active Not Recruiting

MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

Role: lead